Piper Jaffray analyst JP McKim lowered his price target for Inogen to $140 from $185 following last night's Q1 results. The company lowered sales guidance by 5% and EBITD guidance by 3%, yet the stock is indicated down 29% in the after-hours, McKim tells investors in a post-earnings research note. "That does not make a lot of sense to us," he adds. In a research note titled "Business Is Not Broken But Stock Trading Like It; Has Everyone Forgot About G5?," the analyst keeps an Overweight rating on Inogen. McKim says he has the "utmost confidence" that the market is converting to portable oxygen concentrators and Inogen has the best products on the market.